Business context and reporting period
The supplied filing is Amarillo Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014—not a filing under the name Ainos, Inc. The company was developing low-dose oral interferon and was operating as a Chapter 11 debtor-in-possession after filing for bankruptcy protection on October 31, 2013. Its common stock traded as AMARQ on the OTCQB.
Financial results and position
| Metric | Q1 2014 | Q1 2013 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $175,014 | $161,291 |
| Operating loss | $175,014 | $161,291 |
| Net loss | $175,060 | $186,557 |
| Net loss applicable to common shareholders | $183,158 | $194,655 |
| Operating cash used | $110,732 | $178,030 |
| Cash at period end | $3,760 | $6,539 at Dec. 31, 2013; $7,355 at Mar. 31, 2013 |
| Current assets | $26,112 | $68,492 at Dec. 31, 2013 |
| Current liabilities | $5,081,021 | $4,944,318 at Dec. 31, 2013 |
| Stockholders’ deficit | $4,965,945 | $4,782,787 at Dec. 31, 2013 |
Gross margin and margin percentages were not meaningful because there were no sales or cost of revenues. The working capital deficit was $5,054,909. Related-party notes payable were $3,635,015, with another $1,050,746 in accrued related-party interest. The filing reports no cash interest paid in Q1 2014.
Material changes versus the prior period
- Operating expenses increased $13,723: research and development fell 55% to $15,270, while selling, general and administrative expense rose 26% to $159,744, largely due to bankruptcy reorganization costs.
- Net loss declined $11,497, or 6%, primarily reflecting lower interest expense ($46 versus $29,483), partly offset by higher operating loss. The prior-year period included a $4,217 gain from a change in derivative fair value; there was no such gain in 2014.
- Operating cash use improved by $67,298 year over year, but Q1 2014 financing included $107,972 of related-party note proceeds. Cash still declined $2,779 during the quarter.
- Current liabilities increased about $137,000 from year-end, mainly as related-party notes payable rose. No common stock was issued in the quarter.
Outlook, risks and unusual items
- Going concern and bankruptcy: Management said continued losses and lack of liquidity create substantial doubt about the company’s ability to continue. Continued operation depends on confirmation of a reorganization plan, creditor approval, recapitalization, and interim and permanent financing. Failure to reorganize could force the company to cease operations. The filing cautions that existing equity holders may receive little or no recovery.
- Liquidity: Management estimated a cash burn of approximately $50,000 per month. It reported $42,500 of additional Yang Group funding received after March 31 through May 10, 2014. Court approval may be required for financing and other actions outside the ordinary course.
- Product and supply risks: The company had no product sales and did not expect significant sales or royalty revenue for several years. Its former supplier, Hayashibara, halted interferon production and the supply agreement was terminated; the company lacked a current source for clinical trials and was exploring alternatives. Replacing natural interferon with recombinant interferon could require costly and time-consuming repeat studies.
- Debt and related parties: The company was in repayment default on two HBL notes, which HBL had not demanded. Related-party financing included a Yang Group secured revolving note with $280,000 advanced, and a court-approved post-petition facility of up to $285,000, of which $164,972 had been advanced through March 31. A separate director note was also in default.
- Other risks: FDA approval, clinical outcomes, financing availability, third-party manufacturing and distribution, intellectual property, competition, and key-person dependence could materially affect prospects. The filing gave no specific operating or financial guidance.
Important facts for investors to verify
- Confirm the issuer identity: the provided document names Amarillo Biosciences, Inc., although the request metadata names Ainos, Inc.
- Review the status and terms of the Chapter 11 plan, creditor claims, court approvals, and prospects for emergence or liquidation.
- Verify available cash, post-quarter related-party funding, facility advances and remaining borrowing capacity, and the company’s near-term cash needs.
- Reconcile related-party debt and accrued interest, including amounts and priority under the proposed reorganization plan.
- Assess whether an alternative interferon supplier can be secured and what trials, costs, regulatory steps, and timelines would be required.